CytoTools AG has started studies on the efficiency of its active substance DPOCL in COVID-19 through its subsidiary CytoPharma. The test series will be carried out in cooperation with the renowned German university working group Virology of the University Hospital Frankfurt. The aim of the novel treatment is to offer the active ingredient DPOCL in the form of an inhalation solution, e.g. combined with a simple saline solution, which can be nebulized in commercially available inhalers. Tests with freely available inhalers have already been successfully completed. This would enable the virus to be controlled directly in the lungs or in the bronchial region and the upper respiratory tract, at the barrier of entry of the virus into the body, at a very early stage. The known extraordinarily good tolerability of the active ingredient solution offers the advantage here that comparatively complication-free treatment can be started at a very early stage of an infection.